The Oncology Institute, Inc.
TOI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $393,412 | $324,239 | $252,483 | $203,003 |
| % Growth | 21.3% | 28.4% | 24.4% | – |
| Cost of Goods Sold | $339,415 | $264,666 | $200,390 | $162,155 |
| Gross Profit | $53,997 | $59,573 | $52,093 | $40,848 |
| % Margin | 13.7% | 18.4% | 20.6% | 20.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $114,115 | $136,591 | $134,044 | $86,706 |
| Operating Expenses | $114,115 | $136,591 | $134,044 | $86,706 |
| Operating Income | -$60,118 | -$77,018 | -$81,951 | -$45,858 |
| % Margin | -15.3% | -23.8% | -32.5% | -22.6% |
| Other Income/Exp. Net | -$4,545 | -$6,086 | $81,860 | $34,260 |
| Pre-Tax Income | -$64,663 | -$83,104 | -$91 | -$11,598 |
| Tax Expense | $0 | -$36 | -$243 | -$671 |
| Net Income | -$64,663 | -$83,068 | $152 | -$10,927 |
| % Margin | -16.4% | -25.6% | 0.1% | -5.4% |
| EPS | -0.71 | -0.92 | 0.001 | -0.16 |
| % Growth | 22.8% | -102,322.2% | 100.6% | – |
| EPS Diluted | -0.71 | -0.92 | -0.21 | -0.16 |
| Weighted Avg Shares Out | 75,044 | 73,749 | 72,793 | 66,231 |
| Weighted Avg Shares Out Dil | 75,044 | 73,749 | 80,606 | 66,231 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $7,496 | $6,777 | $4,082 | $320 |
| Depreciation & Amortization | $6,287 | $5,873 | $4,411 | $3,341 |
| EBITDA | -$53,831 | -$54,278 | -$67,596 | -$42,041 |
| % Margin | -13.7% | -16.7% | -26.8% | -20.7% |